semaglutide and asthma New research suggests GLP-1 medications like may help reduce flare-ups in people with obesity, showing fewer attacks less need for reliever inhalers. Experts say the results are promising but New Obesity Drugs Linked to
Description
Genetic factors also play a role in how your body responds to GLP-1 therapy

steady-state drug levels are reached after around four to five weeks of weekly dosing

doi:10.1038/npjamd.2016.3 33

Immunocompromised patients, premature infants, critically ill individuals, those with central venous catheters, and patients with severe acute pancreatitis should avoid GLP-1 probiotics due to elevated risk of serious infections and adverse outcomes
Other groups requiring careful evaluation include: Patients with a history of pancreatitis a causal relationship between incretin-based therapies and pancreatitis has not been definitively established, but UK SmPCs advise caution in those with a prior history

[DOI] [PMC free article] [PubMed] [Google Scholar] 130
